ABDELAZIZ ELHADDAD, MD
Medical Oncology Physician · DES MOINES, IA
Individual Active NPI 1447488325
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 766 | 227,735 | $10,684,815 | $5,246,681 | $4,183,906 |
| 2023 | 829 | 206,171 | $7,823,246 | $3,684,208 | $2,933,056 |
| 2022 | 770 | 152,297 | $5,602,723 | $2,942,830 | $2,347,119 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 25,600 | $52 | $41 |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | 17,280 | $0 | $0 |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13,260 | $0 | $0 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 12,000 | $0 | $0 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11,660 | $3 | $2 |
| J0185 | Injection, aprepitant, 1 mg | 10,530 | $2 | $1 |
| J9267 | Injection, paclitaxel, 1 mg | 7,740 | $0 | $0 |
| J0897 | Injection, denosumab, 1 mg | 6,420 | $25 | $20 |
| J1756 | Injection, iron sucrose, 1 mg | 5,200 | $0 | $0 |
| J1930 | Injection, lanreotide, 1 mg | 5,040 | $48 | $38 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 3,420 | $0 | $0 |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 2,772 | $25 | $20 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | MD-41961 | IA |
| Hematology (Internal Medicine) Physician | 207RH0000X | MD-41961 | IA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Iowa
- NPI 1588601157
- NPI 1841254406
- NPI 1225141609
- NPI 1932153822
- NPI 1790136182
- NPI 1295747624
- NPI 1316434574
- NPI 1184604993
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.